Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BCAL Diagnostics Limited ( (AU:BDX) ) has shared an update.
BCAL Diagnostics Limited announced it will host an investor webinar on 24 September 2025, featuring presentations from its Executive Chair and CEO. This event is part of BCAL’s ongoing efforts to engage with investors and stakeholders, potentially impacting its market positioning and stakeholder relations.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited is an Australian biotechnology company focused on early multi-cancer detection. It holds an exclusive license agreement with ClearNote Health Inc. for the distribution of pancreatic and ovarian cancer blood tests in Australia. BCAL is also advancing breast cancer detection through BREASTEST, a non-invasive, lipid-based test designed to complement mammography.
Average Trading Volume: 181,989
Technical Sentiment Signal: Hold
Current Market Cap: A$26.35M
Find detailed analytics on BDX stock on TipRanks’ Stock Analysis page.